The role of CXCR4 in the prediction of bone metastases from breast cancer: A pilot study

Oncology

Volumn 80, Issue 3-4, 2011, Pages 225-231

  Sacanna, Emanuele ^a,c   Ibrahim, Toni ^a   Gaudio, Michele ^a,d   Mercatali, Laura ^a   Scarpi, Emanuela ^c   Zoli, Wainer ^b   Serra, Patrizia ^a   Bravaccini, Sara ^b   Ricci, Rossana ^a   Serra, Luigi ^d   Amadori, Dino ^a  

^a Osteoncology Center   (Italy)

^b Biosciences Laboratory   (Italy)

^c DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^d MORGAGNI PIERANTONI HOSPITAL   (Italy)

Author keywords

Bone metastasis; Breast cancer; CXCR4; Estrogen receptor; HER 2

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PARAFFIN;

AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; VISCERAL METASTASIS;

BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PILOT PROJECTS; RECEPTORS, CXCR4; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 79959840641     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000327585     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12: 6243s-6249s. (Pubitemid 44703797)
3. Galasko C: The anatomy and pathways of skeletal metastases; in Weiss L, Gilbert A (eds): Bone Metastases. Boston, GK Hall, 1981, pp 49-63.
4. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, Coleman RE: Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008; 113: 193-201. (Pubitemid 351976401)
5. Leeming DJ, Hegele A, Byrjalsen I, Hofmann R, Qvist P, Karsdal MA, Schrader AJ, Wagner R, Olbert P: Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers. Cancer Epidemiol Biomarkers Prev 2008; 17: 1269-1276.
6. Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, Schuetz F: Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 2008; 19: 2007-2011.
7. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rucklinger E, Greil R, Marth C: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679-691.
8. Virk MS, Lieberman JR: Tumor metastasis to bone. Arthritis Res Ther 2007; 9(suppl 1):S5.
9. Bussard KM, Gay CV, Mastro AM: The bone microenvironment in metastasis; what is special about bone Cancer Metastasis Rev 2008; 27: 41-55.
10. Vandercappellen J, Van Damme J, Struyf S: The role of CXC chemokines and their receptors in cancer. Cancer Lett 2008; 267: 226-244.
11. Salvucci O, Bouchard A, Baccarelli A, Deschenes J, Sauter G, Simon R, Bianchi R, Basik M: The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat 2006; 97: 275-283. (Pubitemid 43945757)
12. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A: Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56. (Pubitemid 32225831)
13. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. 1. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002; 41: 154-161.
14. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, Mc-Shane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145. (Pubitemid 350003059)
15. Cabioglu N, Yazici MS, Arun B, Broglio KR, Hortobagyi GN, Price JE, Sahin A: CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res 2005; 11: 5686-5693. (Pubitemid 41170291)
16. Cabioglu N, Sahin A, Doucet M, Yavuz E, Igci A, O Yildirim E, Aktas E, Bilgic S, Kiran B, Deniz G, Price JE: Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin Exp Metastasis 2005; 22: 39-46. (Pubitemid 41185860)
17. Cabioglu N, Gong Y, Islam R, Broglio KR, Sneige N, Sahin A, Gonzalez-Angulo AM, Morandi P, Bucana C, Hortobagyi GN, Cristofanilli M: Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol 2007; 18: 1021-1029. (Pubitemid 47050493)
18. Cabioglu N, Sahin AA, Morandi P, Meric-Bernstam F, Islam R, Lin HY, Bucana CD, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M: Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol 2009; 20: 1013-1019.
19. Hao L, Zhang C, Qiu Y, Wang L, Luo Y, Jin M, Zhang Y, Guo TB, Matsushima K, Zhang Y: Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer. Cancer Lett 2007; 253: 34-42. (Pubitemid 46881198)
20. Furusato B, Mohamed A, Uhlén M, Rhim JS: CXCR4 and cancer. Pathol Int 2010; 60: 497-505.
21. Bohn OL, Nasir I, Brufsky A, Tseng GC, Bhargava R, MacManus K, Chivukula M: Biomarker profile in breast carcinomas presenting with bone metastasis. Int J Clin Exp Pathol 2009; 3: 139-146.
22. Chiang AC, Massague J: Molecular basis of metastasis. N Engl J Med 2008; 359: 2814-2823.
23. Kominsky SL, Davidson NE: A 'bone' fide predictor of metastasis? Predicting breast cancer metastasis to bone. J Clin Oncol 2006; 24: 2227-2229. (Pubitemid 46630649)
24. Silvestrini R, Daidone MG, Luisi A, Boracchi P, Mezzetti M, Di Fronzo G, Andreola S, Salvadori B, Veronesi U: Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol 1995; 13: 697-704.
25. Volpi A, De Paola F, Nanni O, Granato AM, Bajorko P, Becciolini A, Scarpi E, Riccobon A, Balzi M, Amadori D: Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study. Breast Cancer Res Treat 2000; 63: 181-192.
26. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365: 671-679. (Pubitemid 40260888)
27. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3: 537-549. (Pubitemid 36808649)
28. Gupta GP, Minn AJ, Kang Y, Siegel PM, Serganova I, Cordon-Cardo C, Olshen AB, Gerald WL, Massague J: Identifying site-specific metastasis genes and functions. Cold Spring Harb Symp Quant Biol 2005; 70: 149-158. (Pubitemid 44124866)
29. Wei B, Wang J, Bourne P, Yang Q, Hicks D, Bu H, Tang P: Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas. Hum Pathol 2008; 39: 1809-1815.
30. Ben-Baruch A: Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis 2008; 25: 345-356. (Pubitemid 351748979)
31. Schimanski CC, Schwald S, Simiantonaki N, Jayasinghe C, Gonner U, Wilsberg V, Junginger T, Berger MR, Galle PR, Moehler M: Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res 2005; 11: 1743-1750. (Pubitemid 40471835)
32. Kang H, Watkins G, Douglas-Jones A, Mansel RE, Jiang WG: The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer. Breast 2005; 14: 360-367. (Pubitemid 41510192)
33. Andre F, Cabioglu N, Assi H, Sabourin JC, Delaloge S, Sahin A, Broglio K, Spano JP, Combadiere C, Bucana C, Soria JC, Cristofanilli M: Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 2006; 17: 945-951. (Pubitemid 43778984)
34. Schmid BC, Rudas M, Rezniczek GA, Leodolter S, Zeillinger R: CXCR4 is expressed in ductal carcinoma in situ of the breast and in atypical ductal hyperplasia. Breast Cancer Res Treat 2004; 84: 247-250. (Pubitemid 38445374)
35. Kato M, Kitayama J, Kazama S, Nagawa H: Expression pattern of CXC chemokine receptor-is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res 2003; 5: 144-150.
36. Shim H, Lau SK, Devi S, Yoon Y, Cho HT, Liang Z: Lower expression of CXCR4 in lymph node metastases than in primary breast cancers: potential regulation by ligand-dependent degradation and HIF-1alpha. Biochem Biophys Res Commun 2006; 346: 252-258. (Pubitemid 43865990)
37. Huang YC, Hsiao YC, Chen YJ, Wei YY, Lai TH, Tang CH: Stromal cell-derived factor-1 enhances motility and integrin up-regulation through CXCR4, ERK and NF-kappaBdependent pathway in human lung cancer cells. Biochem Pharmacol 2007; 74: 1702-1712.
38. Andre F, Xia W, Conforti R, Wei Y, Boulet T, Tomasic G, Spielmann M, Zoubir M, Berrada N, Arriagada R, Hortobagyi GN, Hung MC, Pusztai L, Delaloge S, Michiels S, Cristofanilli M: CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist 2009; 14: 1182-1188.
39. Xiang ZL, Zeng ZC, Tang ZY, Fan J, Zhuang PY, Liang Y, Tan YS, He J: Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival. BMC Cancer 2009; 9: 176.
40. Sun YX, Schneider A, Jung Y, Wang J, Dai J, Wang J, Cook K, Osman NI, Koh-Paige AJ, Shim H, Pienta KJ, Keller ET, McCauley LK, Taichman RS: Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 2005; 20: 318-329.
41. Kaift JT, Yekebas EF, Schurr P, Obonyo D, Wachowiak R, Busch P, Heinecke A, Pantel K, Izbicki JR: Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 2005; 97: 1840-1847. (Pubitemid 43033904)
42. Wang N, Wu QL, Fang Y, Mai HQ, Zeng MS, Shen GP, Hou JH, Zeng YX: Expression of chemokine receptor CXCR4 in nasopharyngeal carcinoma: pattern of expression and correlation with clinical outcome. J Trans Med 2005; 3: 26.
43. Sauvé K, Lepage J, Sanchez M, Heveker N, Tremblay A: Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway. Cancer Res 2009; 69: 5793-5800.
44. Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, Hung MC: Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 2004; 6: 459-469. (Pubitemid 39469982)